<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05088161</url>
  </required_header>
  <id_info>
    <org_study_id>JJDB-SR-2021-02</org_study_id>
    <nct_id>NCT05088161</nct_id>
  </id_info>
  <brief_title>Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques</brief_title>
  <official_title>Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we will use high-throughput proteomics techniques to search for biomarkers of&#xD;
      post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed&#xD;
      with pancreatic cancer through bioinformatics analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study plan from the affiliated hospital of Qingdao university collected 20 cases of&#xD;
      patients with pancreatic cancer pathological tissue samples and clinical data, including&#xD;
      clinical diagnostic information, laboratory tests, imaging examination results and other&#xD;
      information data), through high-throughput proteomic technology in pancreatic cancer&#xD;
      pathological finding biomarkers, the bioinformatics analysis to explore the prognosis&#xD;
      biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2021</start_date>
  <completion_date type="Anticipated">March 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differentially expressed proteins in tumor and paracancer tissues</measure>
    <time_frame>180 Days</time_frame>
    <description>Two dimensional gel electrophoresis, mass spectrometry and other techniques were used to separate and compare pancreatic cancer tissues and normal adjacent tissues to search for differentially expressed proteins.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Patients</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects in this study were all patients with pathologically diagnosed pancreatic&#xD;
        cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of Chinese nationality, age and gender are not limited.&#xD;
&#xD;
          -  Pathologically confirmed pancreatic cancer patients.&#xD;
&#xD;
          -  Pathological specimens were archived tumor tissue samples after a diagnosis of&#xD;
             pancreatic cancer.&#xD;
&#xD;
          -  Clinical diagnostic information was complete three months before sampling.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a second primary tumor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Cao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>the study director of phase I clinical research center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Cao, Doctor</last_name>
    <phone>86-18661809090</phone>
    <email>caoyu1767@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phase I Clinical Research Center</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Cao, Doctor</last_name>
      <phone>86-18661809090</phone>
      <email>caoyu1767@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

